Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Repurposing of drugs for combined treatment of COVID-19 cytokine storm using machine learning

Maanakumar R. Gantla a, Igor F. Tsigelny b,c,d,*, Valentina L. Kouznetsova b,c

a MAP Program, UC San Diego, Calif, USA
b San Diego Supercomputer Center, UC San Diego, Calif, USA
c BiAna, La Jolla, Calif, USA
d Dept. of Neurosciences, UC San Diego, Calif, USA

ARTICLE INFO

Keywords:
COVID-19
SARS-CoV-2
Docking
Machine learning
Multi-targeted drug discovery
Screening of FDA-approved drugs

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced cytokine storm is the major cause of COVID-19 related deaths. Patients have been treated with drugs that work by inhibiting a specific protein partly responsible for the cytokines production. This approach provided very limited success, since there are multiple proteins involved in the complex cell signaling disease mechanisms. We targeted five proteins: Angiotensin II receptor type 1 (AT1R), a disintegrin and metalloprotease 17 (ADAM17), Nuclear Factor Kappa B (NFκB), Janus kinase 1 (JAK1) and Signal Transducer and Activator of Transcription 3 (STAT3), which are involved in the SARS-CoV-2 induced cytokine storm pathway. We developed machine-learning (ML) models for these five proteins, using known active inhibitors. After developing the model for each of these proteins, FDA-approved drugs were screened to find novel therapeutics for COVID-19. We identified twenty drugs that are active for four proteins with predicted scores greater than 0.8 and eight drugs active for all five proteins with predicted scores over 0.85. Mitomycin C is the most active drug across all five proteins with an average prediction score of 0.886. For further validation of these results, we used the PyRx software to conduct protein-ligand docking experiments and calculated the binding affinity. The docking results support findings by the ML model. This research study predicted that several drugs can target multiple proteins simultaneously in cytokine storm-related pathway. These may be useful drugs to treat patients because these therapies can fight cytokine storm caused by the virus at multiple points of inhibition, leading to synergistically effective treatments.

1. Introduction

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in millions of infected patients and deaths worldwide [1,2]. Patients frequently encountered complications with significant mortality, particularly by acute respiratory distress syndrome (ARDS) with a broad spectrum of issues such as multiple-organ failure, and blood clots [3,4]. There has been tremendous amount of research going on towards discovering therapeutics for the COVID-19, and few drugs have been approved by FDA such as remdesivir, Paxlovid and molnupiravir, and all of them mainly target viral proteins [5,6].

Mounting research data reveals that the severity of COVID-19 is mainly associated with an increased level of inflammatory mediators including cytokines and chemokines such as interleukin IL-2, IL-7, IL-8, IL-9, IL-10, IL-17, tumor necrosis factor alpha (TNFα), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1 alpha (MIP1α), granulocyte colony stimulating factor (G-CSF),...
C-X-C chemokine ligand 10 (CXCL10), C-reactive protein, ferritin, and D-dimers in blood upon SARS-CoV-2 infection [7-13]. More specifically, patients in intensive care unit (ICU) showed higher levels of plasma inflammatory cytokines compared to non-ICU patients [14], and therefore fatal COVID-19 is characterized as a cytokine release syndrome (CRS) that is caused by a cytokine storm. Thus, targeting proteins responsible for cytokine storm serves as a possible mechanism of treatment for severe COVID-19 patients [15-17].

The SARS-CoV-2 induced cytokine storm pathway [18] shows that there are multiple proteins involved in the disease signaling mechanisms. Cytokines are cell signaling, small protein molecules that aid cell to cell communication in immune responses and stimulate the movement of cells towards sites of inflammation, infection, and trauma [19]. Cytokine Storm is essentially an unregulated immune response characterized by an excessive release of multiple pro-inflammatory cytokines [20,21].

It has been identified that proteins such as Angiotensin II receptor type 1 (AT1R), A disintegrin and metalloprotease 17 (ADAM17), Nuclear Factor-Kappa B (NF-kB), Janus kinase 1 (JAK1) and Signal transducer and activator of transcription 3 (STAT3) are implicated in the production of pro-inflammatory cytokines and are considered as a promising COVID-19 therapeutic targets [15]. Therefore, discovering a drug that can interfere with function of either all of the proteins or most of them synergistically would become an effective therapeutic. Based on literature search, as of now there are no such therapeutics exist. Discovery of novel effective drugs and therapies for COVID-19 is critical for tackling the disease. However, discovery and development of effective therapies can be costly and time-consuming. For this reason, it would be ideal to repurpose already existing FDA-approved drugs given the proven safety, if they can also interfere effectively with proteins responsible for cytokine storm.

In this pathway, we have investigated five proteins: AT1R, ADAM17, NF-kB, JAK1, and STAT3. AT1R signaling axis activates ADAM17, which results in the production of cytokines TNFα and IL-6. The IL-6 amplifier plays a critical role in chronic inflammatory diseases. Activation of NF-kB, JAK1 and STAT3 triggers the IL-6 amplifier, which causes the cytokine storm and leads to the ARDS and multiple-organ failure. Targeting these five proteins would prevent cytokine storm to yield the best potent COVID-19 drug.

Conventional methods of drug discovery are very expensive, complex processes that takes several years to bring drugs to the clinic. We used machine learning to expedite the drug discovery process by screening FDA drugs, so that the treatment for COVID-19 is available sooner.

Recently, machine learning (ML) has emerged as an important computational technique and has been applied to various tasks in drug discovery, such as molecular property prediction and drug-target interaction prediction. Given the great advantage of this computational tool in terms of the cost and time, in this project we have used ML classification model with a random forest algorithm in WEKA software [22] for repurposing of some FDA-approved drugs for use as COVID-19 therapeutics. These predictions can then be confirmed through structure-based virtual screening, specifically using docking simulators PyRx. The docking provides the binding energy for each conformer and helps validate the accuracy of prediction.

2. Materials and methods

All research was completed in silico. The programs, tools, and websites used: PubChem, ZINC database subsection covering FDA-approved drugs, Protein Data Bank (PDB), Pharmaceutical Data Exploration Laboratory (PaDEL)-Descriptor, Waikato Environment for Knowledge Analysis (WEKA), PyRx, Discovery Studio Visualizer. A flowchart of methods is presented in Fig. 1.

2.1. Data collection

Data for known active inhibitors and a control set of random compounds obtained from PubChem are listed in Table 1. Data for FDA-approved drugs obtained from the ZINC database. Activity values and SMILES (Simplified Molecular-Input Line-Entry System) [23] files for compounds tested with the proteins AT1R, ADAM17, NF-kB, JAK1, and STAT3 were retrieved from PubChem. To limit the tested compounds to the strongest inhibitors, compounds with top 100 IC50 values were chosen for training the model. One-thousand-six-hundred-fifteen FDA-approved drugs and their SMILES were retrieved from ZINC database.

The chemical structures are obtained in SMILES format. These files are 1D ASCII strings that represent 3D molecular structure. An example of top ten inhibitors for AT1R are shown in Table 2.

2.2. Molecular descriptor calculation

PaDEL-Descriptor software [24] is used to calculate the molecular descriptors for the compounds. These descriptors are the characteristics of the compound that are used for training of the ML model. For example, number of aromatic rings, number of pi bonds, molecular weight, atom count, etc. The software currently calculates 1875 descriptors (1444 1D and 2D descriptors and 431 3D descriptors) and 12 types of fingerprints. For our model building we have used 1444 1D and 2D descriptors.

2.3. InfoGain filtering in WEKA to select top 100 descriptors

To narrow down the calculated 1D and 2D descriptors from 1444 to only the most significant ones, we utilized attribute selection from WEKA [25], an open-source ML software. The descriptors were ranked by the Information Gain Attribute Evaluation (InfoGain) function, an unsupervised machine-learning algorithm, that measures how important each descriptor is in determining whether a given molecule is an inhibitor or not. InfoGain measures how each feature contributes to decreasing the overall computational entropy. Only the most significant descriptors were selected to be used by the ML model to reduce noise.

2.4. Building a machine-learning model

Machine-learning model for each protein was built using WEKA [22]. WEKA provides both standard and extensive ML functionality, integrated within classification, regression, clustering and other pattern recognition capabilities. Data for the model is prepared by taking top 100 descriptors of top 100 inhibitors for each of the proteins and 100 control set of random molecules.

First, we submitted the prepared inhibitor file containing selected random compounds with their molecular descriptors into WEKA. Then used the Random Forest algorithm 10-folds cross validation to build the model. Also, we used Random Forest algorithm with an 80/20% training-testing split to evaluate the performance of the model. Such the training-testing split ensures that there is no overfitting as 20% of the data. It was not used to build the model but used for testing. Then we analyzed the model accuracy and elucidated the ROC curves. Saved model was used in the next step to screen FDA-approved drugs. The Receiver Operating Characteristic (ROC) curves were calculated to measure the effectiveness of the model. ROC curve summarizes the prediction performance of a classification model at all classification thresholds. Fig. 2a–2e present the ROC graphs for machine-learning models of proteins AT1R, ADAM17, NF-kB, JAK1, and STAT3. Model accuracy is 91.5–99.0% range and Area Under the Receiver-Operating Characteristic curve (AUC) is 0.97–1.00. That values confirm the accuracy of the models. Receiver-Operating Characteristic (ROC) curves for five proteins are shown in Fig. 2.
2.5. Screening of FDA-approved drugs using the model

FDA approved drugs are downloaded from ZINC database [26]. Using PaDEL-Descriptor software, the molecular descriptors were calculated for all the downloaded 1665 FDA-approved drugs. Out of 1444 descriptors, the same 100 descriptors were selected as the training set of the corresponding protein inhibitors. These were then screened with the ML model built using WEKA. The output was analyzed for the prediction scores and the predicted drugs were ranked based on the ML predicted score. The predicted drugs were ranked for each protein and averaged the score among all five proteins listed in Table S1 (Supplementary information).

| Table 1 | Known inhibitors obtained from PubChem. |
|-----------------|-----------------|-----------------|
| Protein | Number of Known Inhibitors | IC50 values range (μM) |
| AT1R | 1192 | 0.00005–19.98 |
| ADAM17 | 1813 | 0.000026–44.0 |
| NF-κB | 348 | 0.003–49.6 |
| JAK1 | 4596 | 0.000013–39.81 |
| STAT3 | 588 | 0.0084–48.0 |

| Table 2 | The top ten inhibitors for AT1R. |
|-----------------|-----------------|-----------------|
| Compound | IC50 (nM) | \[100148\] |
| BDBM50049199 | 0.05 | |
| Saralasin | 0.06 | |
| 2Botbmip | 0.08 | |
| CHEMBL42775 | 0.01 | |
| CHEMBL158809 | 0.01 | |
| CHEMBL298417 | 0.01 | |
| BDBM50283219 | 0.01 | |
| BDBM50283237 | 0.01 | |
| BDBM50283194 | 0.01 | |
| BDBM50283245 | 0.01 | |
Fig. 2. Accuracies and AUROC of the predictions of inhibitors for five proteins related to cytokine storm in COVID-19: (a) AT1R Accuracy 98.5% and AUROC 99%; (b) ADAM17 Accuracy 98.5% and AUROC 99%; (c) NF-κB Accuracy 96%, AUROC 99%; (d) JAK1 Accuracy 98.5%, AUROC 100%; (e) STAT3 Accuracy 91.5%, AUROC 97.8%.
2.6. Docking of predicted FDA-approved drugs to selected proteins

To confirm the activity and binding to the protein, docking of predicted FDA-approved drugs was performed using PyRx tool [27] with Discovery Studio software [28] to visualize the results. For docking the selected compounds, the crystal structure of the protein was downloaded from PDB [29,30] for each of the five proteins. PDB IDs for selected proteins are AT1R—4ZUD, ADAM17—2FV5, NF-xB—1SVC, JAK1—4E14, and STAT3—6NUQ. A binding active site is defined for each protein based on the reported ligand interactions with protein. To validate the specificity of the docked compounds, docking of random compounds was also conducted. A random number generator without repetition was used to obtain 100 random compound IDs and to select entries from the PubChem database that correspond to the random numbers obtained.

Each of the five proteins’ 3D structure with a known ligand was downloaded from the PDB database. Each predicted FDA-approved drug’s 3D structure was downloaded from PubChem. From each downloaded protein–ligand complex, the ligand was removed in Discovery Studio and remained protein was loaded into PyRx. The active sites of each protein were defined as a box that encompasses residues of the binding site. Then we ran the AutoDock Wizard for the top 12 predicted compounds, 12 best-activity known compounds, and 12 random compounds with each protein. For each compound nine conformers were generated and docked. In total there were generated 324 conformers, which were docked to each protein. The docked protein–ligand complexes were analyzed to elucidate the interactions of compounds with amino-acid residues. Binding Free Energy values are listed in Table 8.

3. Results

3.1. Machine-learning prediction results

The results of the ML models’ predictions were evaluated using confusion matrices and their derivatives: the accuracy (ACC), precision (PREC), Matthews correlation coefficient (MCC), true-positive rate (TPR) or recall (REC), false-positive rate (FPR), as well as the area under the receiver operating characteristic (ROC) curve (AUROC), and the area under the precision-recall curve (PRC area).

The weighted averages for each of these metrics are listed in Table 3. The ROC curve compares the sensitivity and specificity across a range of values. Thus, the vertical axis is the TPR, that is, the sensitivity or recall; and the horizontal axis is the FPR or (1 – specificity). The FPR is the probability of falsely classifying a positive class. The model’s low FPR of 0.015 to 0.040 demonstrates a low probability of wrongly classifying an inactive compound to active one. The TPR (sensitivity) is the probability of correctly classifying a positive class. The model’s high TPR of 0.915 to 0.985 indicates a high probability of correctly classifying an active compound. The large average AUROC value 0.978 to 1.0 indicates that the classification is accurate. Another way to evaluate the performance of the proposed method is the PRC area, which shows precision values for the corresponding sensitivity (recall, i.e., TPR) values. The model’s large PRC area value of 0.979 to 1.0 again shows the good performance of our method for all the five proteins.

The predicted drugs were ranked for each protein and averaged the score among all five proteins listed in Table S1 (Supplementary information). Total 45 compounds found to be active inhibiting all five proteins AT1R, ADAM17, NF-xB, STAT3, JAK1. Forty-five active compounds with the greater than 0.6 average predictive score is shown in Table S1.

Top eight FDA-approved drugs predicted active for all five proteins AT1R, ADAM17, NF-xB, STAT3, and JAK1 are shown in Table 4.

Top 20 FDA-approved drugs predicted active for four proteins (AT1R, ADAM17, NF-xB, STAT3) showed an average score of greater than 0.83 are shown in Table 5.

Thirteen drugs (Table 5) showed average scores of greater than 0.9. Abacavir and raltegravir (Table 5) showed top average scores of 0.96. Chemical structures of top active compounds are shown in Fig. 3.

Current use of predicted active drugs is shown in Table S2 (Supplementary information).

3.2. Docking results

Docking of the top three predicted FDA-approved drugs mitomycin C, abacavir and raltegravir with the proteins’ binding sites are shown in Fig. 4 and Fig. 5.

Mitomycin C docked with all five proteins showed binding affinity ranging from −6.0 to −7.5 kcal/mol (Table 6).

Abacavir docked with four proteins showed binding free energy ranging from −6.1 to −8.6 kcal/mol (Table 7). Raltegravir docked with four proteins showed binding energy ranging from −7.4 to −9.6 kcal/mol (Table 7) which is considered as reasonable binding affinity.

Binding affinities calculated using PyRx docking for the top 12 compounds. Table 8 lists the top predicted active compounds docked for all five proteins.

The box plots (Fig. 6) demonstrated that the predicted inhibitors had the better binding affinities than known and random compounds. They were constructed using binding affinities obtained from docking for predicted compounds, known inhibitors and control random compounds and are shown in Fig. 6. Docking free energies are listed in Table S3 (Supplementary information).

The box plots (Fig. 6) demonstrates that the predicted inhibitors had an average binding affinity of −6.40 kcal/mol (NF-xB) to −8.37 kcal/mol for AT1R (Fig. 6a), which was better than that of known inhibitors, which had an average of −6.0 kcal/mol for STAT3 (Fig. 6c) to −7.63 kcal/mol for AT1R (Fig. 6). The control group of random molecules had an average binding affinity of −4.78 kcal/mol for NF-xB (Fig. 6c) to −7.0 kcal/mol for ADAM17 (Fig. 6b). This confirms that the predicted inhibitors performed statistically better than the control group.

In this study, five crucial proteins—AT1R, ADAM17, NF-xB, JAK1, STAT3—playing the important roles in cytokine production pathway are targeted to predict the best potential drug for treatment of...
COVID-19 cytokine storm. Number of known inhibitors with reported \( IC_{50} \) values for each protein obtained from PubChem were 1192, 1813, 348, 4596, and 588 respectively. Machine learning models developed exhibited an accuracy ranging from 91.5 to 99.0%, with their AUROC values ranging from 0.98 to 1.0, which is considered as excellent predictive performance of the models.

The box plots (Fig. 6) show that the predicted active compounds have better binding energies than the already known inhibitors and control set of random compounds. One can see that the predicted inhibitors had an average binding affinity of \(-6.40\) kcal/mol (NF-\( \kappa \)B) to \(-8.37\) kcal/mol (AT1R), which was better than that of known inhibitors, which had an average of \(-6.0\) kcal/mol (STAT3) to \(-7.63\) kcal/mol (AT1R). The control group of random molecules had an average binding affinity of \(-4.78\) kcal/mol (NF-\( \kappa \)B) to \(-7.0\) kcal/mol (ADAM17). This confirms the predicted inhibitors performed statistically better than the control group.

From the docking results, binding free energy values ranging from \(-6.0\) to \(-9.6\) kcal/mole targeted for five and four proteins confirms that the predicted compounds bind at the active site of the proteins. The amino acids that showed interaction in the docking experiments for the top three drugs mitomycin C, abacavir and raltegravir are listed in Table 9.

**Table 4**

| Name of Predicted Inhibitor | Prediction score | Average score | ML Rank |
|----------------------------|-----------------|---------------|---------|
| AT1R ADAM17 NF-\( \kappa \)B JAK1 STAT3 |
| Mitomycin C | 0.99 | 0.76 | 0.90 | 0.78 | 1.00 | 0.886 | 1 |
| Valrubicin | 0.97 | 0.73 | 1.00 | 0.71 | 1.00 | 0.882 | 2-3 |
| Pomalidomide | 1.00 | 0.76 | 0.92 | 0.73 | 1.00 | 0.882 | 2-3 |
| Fludarabine | 1.00 | 0.73 | 0.94 | 0.73 | 1.00 | 0.880 | 4 |
| Clarithromycin | 0.99 | 0.70 | 0.95 | 0.72 | 1.00 | 0.872 | 5-6 |
| Trabectedin | 0.99 | 0.75 | 0.91 | 0.71 | 1.00 | 0.872 | 5-6 |
| Capreomycin | 1.00 | 0.70 | 0.89 | 0.75 | 1.00 | 0.868 | 7 |
| Sonidegib | 0.91 | 0.72 | 0.94 | 0.71 | 0.98 | 0.852 | 8 |

Mitomycin C (Table 4) is top ranked FDA drug across all five proteins with average prediction score of 0.886.

**Table 5**

| Name of Predicted Inhibitor | Prediction score | Average score | ML Rank |
|----------------------------|-----------------|---------------|---------|
| AT1R ADAM17 NF-\( \kappa \)B STAT3 |
| Abacavir | 0.93 | 0.73 | 1.00 | 1.00 | 0.9600 | 1-2 |
| Raltegravir | 0.73 | 0.74 | 0.98 | 0.89 | 0.9600 | 1-2 |
| Saxagliptin | 0.99 | 0.88 | 0.97 | 1.00 | 0.9250 | 3-4 |
| Valrubicin | 0.97 | 0.73 | 1.00 | 1.00 | 0.9250 | 3-4 |
| Pomalidomide | 1.00 | 0.76 | 0.92 | 1.00 | 0.9200 | 5 |
| Nimodipine | 0.97 | 0.72 | 0.95 | 1.00 | 0.9175 | 6-7 |
| Fludarabine | 1.00 | 0.73 | 0.94 | 1.00 | 0.9175 | 6-7 |
| Suvorexant | 0.95 | 0.72 | 1.00 | 1.00 | 0.9150 | 8 |
| Boceprevir* | 0.72 | 0.72 | 0.99 | 0.97 | 0.9125 | 9-11 |
| Mitomycin C | 0.99 | 0.76 | 0.90 | 1.00 | 0.9125 | 9-11 |
| Trabectedin | 0.99 | 0.75 | 0.91 | 1.00 | 0.9125 | 9-11 |
| Saquinavir | 0.99 | 0.88 | 0.97 | 1.00 | 0.9100 | 12-13 |
| Clarithromycin* | 0.99 | 0.70 | 0.95 | 1.00 | 0.9100 | 12-13 |
| Capreomycin | 1.00 | 0.70 | 0.89 | 1.00 | 0.8975 | 14-16 |
| Balsalazine | 0.93 | 0.71 | 0.96 | 0.94 | 0.8875 | 14-16 |
| Sonidegib | 0.91 | 0.72 | 0.94 | 0.98 | 0.8875 | 14-16 |
| Minocycline | 0.73 | 0.74 | 0.98 | 0.89 | 0.8850 | 17 |
| Eribulin | 0.92 | 0.71 | 0.86 | 1.00 | 0.8500 | 18 |
| Isradipine | 0.98 | 0.72 | 0.94 | 1.00 | 0.8350 | 19-20 |
| Cangrelor | 0.96 | 0.70 | 0.95 | 1.00 | 0.8350 | 19-20 |

*Boceprevir [31] showed in-vitro activity for COVID-19.
**Clarithromycin [32,33] is in clinical trials to treat COVID-19.

Fig. 3. Chemical structures of the top predicted active for treatment of cytokine storm FDA-approved drugs: (a) mitomycin C; (b) abacavir; (c) raltegravir.
From Table 9 one can see that AT1R’s binding residues—Tyr35, Trp84, Val108, Arg167, and Ile288—are common for mitomycin C, abacavir and raltegravir; ADAM17’s binding residues—Glu406, His405, Ile438, and Ala439—are common for abacavir and raltegravir; NF-κB’s binding residues—Lys52, Ala73, and Glu341—are for abacavir and raltegravir; JAK1’s binding residues—Asp1042, Gly884, and His885—are common for abacavir and raltegravir; STAT3’s binding residue—Ser381—is for abacavir and raltegravir binding to STAT3.

Fig. 4. Docking of mitomycin C with proteins: (a) AT1R; (b) ADAM17; (c) NF-κB; (d) JAK1; (e) STAT3.
Fig. 5. Docking of abacavir and raltegravir with proteins: (a) AT1R–abacavir; (b) ADAM17–abacavir; (c) NF-κB–abacavir; (d) JAK1–abacavir; (e) STAT3–abacavir; (f) AT1R–raltegravir; (g) ADAM17–raltegravir; (h) NF-κB–raltegravir; (i) JAK1–raltegravir; (j) STAT3–raltegravir.
Table 6
Binding free energy for mitomycin C.

| Protein | Binding free energy (kcal/mol) |
|---------|-------------------------------|
| AT1R    | −7.5                          |
| ADAM17  | −7.0                          |
| NF-κB   | −6.0                          |
| JAK1    | −7.2                          |
| STAT3   | −6.5                          |

Table 7
Binding free energy for abacavir and raltegravir.

| Protein | Binding Free energy with abacavir (kcal/mol) | Binding Free energy with raltegravir (kcal/mol) |
|---------|-----------------------------------------------|-----------------------------------------------|
| AT1R    | −7.8                                          | −9.4                                          |
| ADAM17  | −8.6                                          | −9.6                                          |
| NF-κB   | −6.1                                          | −7.4                                          |
| STAT3   | −7.2                                          | −8.3                                          |

Table 8
Binding free energies of the top 12 ML-predicted FDA-approved drugs docked using PyRx software.

| Compound | Binding free energy to |
|----------|------------------------|
|          | AT1R | ADAM17 | NF-κB | JAK1 | STAT3 |
| Mitomycin C | −9.2 | −7.9 | −6.1 | −7.4 | −6.7 |
| Pomalidomide | −8.5 | −7.1 | −5.9 | −8.3 | −7.2 |
| Fludarabine | −8.1 | −9.1 | −6.2 | −8.1 | −7.5 |
| Sonidegib | −10.1 | −10.1 | −7.3 | −9.1 | −8.5 |
| Abacavir | −9.6 | −8.5 | −7.8 | −10.1 | −7.9 |
| Raltegravir | −7.8 | −7.5 | −6.1 | −7.7 | −7.2 |
| Saxagliptin | −7.3 | −8.6 | −5.3 | −6.9 | −5.9 |
| Nimodipine | −7.9 | −6.2 | −6.4 | −8.4 | −7.5 |
| Suvorexant | −9.4 | −8.9 | −7.4 | −9.7 | −8.3 |
| Boceprevir | −8.6 | −9.6 | −6.8 | −7.4 | −7.8 |
| Balsalazide | −7.5 | −7.1 | −6.0 | −7.2 | −6.5 |
| Minocycline | −6.5 | −7.0 | −5.6 | −7.2 | −6.1 |
These results support the idea that the compounds are binding at the active site of protein and not at the non-bonding sites, thus proving that these compounds could act specifically on the protein makes them some of the most promising candidates to treat COVID-19.

4. Discussion

The main goal of this study was to predict the drugs that can target as many as possible cytokine-related genes. We know that there is a
number of such genes that are activated in response on SARS-CoV-2 viral proteins. Here we have a problem that is eternal for medicine. We cannot prescribe more drugs than a set that would be tolerated by the organism. Here we selected five genes that have to be targets of inhibiting agent to prevent the cytokine storm or just decrease the immune response to viral agents. Our model predicted drugs that can simultaneously target at least four of such cytokine-related genes. Based on model’s average prediction scores over 0.6, 45 FDA-approved drugs were predicted active, with 20 drugs having predicted scores greater than 0.8 for 4 proteins (AT1R, ADAM17, NF-κB, JAK1, STAT3). Mitomycin C is the most active drug across all five proteins with an average prediction score of 0.868. Abacavir and raltegravir are the top active compounds for four proteins with average scores of 0.96.

We predicted several drugs that can target simultaneously several proteins in cytokine storm related pathway. These may be useful drugs to treat patients because these therapies can fight cytokine storm caused by the virus at multiple points of inhibiting, leading to synergistically effective treatments.

Mitomycin C ranked top with highest average scores for all five proteins suggesting that it possesses all required chemical functional groups with desired spatial arrangements, so that it can interact and bind well with all proteins. Mitomycin C is approved drug for cancer but has several side effects such as bone marrow suppression and septicaemia because of leukopenia and needs to be further evaluated in clinical experiments. We need to note that despite of clinical usage in multiple cancers, mitomycin C has been reported with several side-effects and listed as potent DNA crosslinker. Furthermore, mitomycin C is a probable human carcinogen, classified as weight-of-evidence Group B2 under the EPA Guidelines for Carcinogen Risk. Abacavir and raltegravir with excellent predictive scores for four proteins (except JAK1), suggesting that changes in chemical structure of the drugs made the difference in biological activity.

Two of predicted drugs—boceprevir [31] and clarithromycin [32,33] are already tested for COVID-19 treatment.

5. Conclusions

Our hypothesis is that it is possible to develop a valid predicting machine-learning model to select the drugs that would target multi-protein pathways for treatment of the COVID-19 cytokine storm is confirmed and gave the model accuracy ranging from 91.5 to 99%, with AUROC ranging from 0.978 to 1.0, considered as excellent predictive performance of the models.

This study not only provides drug candidates that could treat COVID-19, but it also demonstrates the application of predictive models for multitarget drug discovery approach with machine learning.

Future steps for this project would be to confirm the inhibitory activity of the predicted drugs against the target proteins in animal models. We need to note that there are differences between the binders (identified by computational screening) and the therapeutic active drugs for specific diseases. The formers have to be further tested in pharmacology experiments to know their actual action modes (agonism, antagonism, inhibitory effect or so on). These drugs definitely need to be tested in pharmacological experiments to establish the mechanism of action before a clinical use. The methods of this study could be extended to predictive models for discovering therapeutics for other disease areas, such as chronic inflammatory diseases.

CRediT authorship contribution statement

Maanaskumar R. Gantla: Methodology, Software, Formal analysis, Data curation, Writing – original draft. Igor F. Tsigelny: Methodology, Project administration. Valentina L. Kouznetsova: Conceptualization, Methodology, Validation, Writing – review & editing, Supervision.

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] World Health Organization (WHO). Coronavirus Disease 2019 (COVID-19) Situation Report: Weekly epidemiological Update on COVID-19. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
[2] Johns Hopkins University & Medicine: Coronavirus Resource Center https://coronavirus.jhu.edu.
[3] Hsu CY, Lai CC, Yeh YP, Chuane CC, Chen HH. Progression from Pneumonia to ARDS as a Predictor for Fatal COVID-19. J Infect Public Health 2021; 14: 504-507.
[4] Aslan A, Aslan C, Zolbanin NM, Jafari R. Acute respiratory distress syndrome in COVID-19 patients: Characteristics and development of Therapeutics for COVID-19. mSystems 2021; 6: 374. https://doi.org/10.1128/mSystems.00233-21.
[5] Robinsona PC, Liew DFL, Tannera HL, Graingerf JR, Dwekg RA, Reisler RB, et al. COVID-19 therapeutics: Challenges and directions for the future. PNAS 2022;119:1-10. https://doi.org/10.1073/pnas.2119893119.
[6] Ranbo HM, Wellhausen N, Gbosh S, Lee AJ, Dollott AA, Hu F, et al. Greene CS. Identification and Development of Therapeutics for COVID-19. mSystems 2021; 6: 1–52. https://journals.asm.org/doi/10.1128/mSystems.00233-21.
[7] Tay MZ, Lai OC, Yeh VP, Chuane CC, Chen HH. Progression from Pneumonia to ARDS as a Predictor for Fatal COVID-19. J Infect Public Health 2021; 14: 504-507. https://doi.org/10.1016/j.jiph.2020.12.026.
[8] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130 (5):2620-9. https://doi.org/10.1172/JCI117244.
[9] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395(10223):507-13. https://doi.org/10.1016/S0140-6736(20)30211-7.
[10] Kim KY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, et al. Viral load kinetics of SARS-CoV–2 infection in first two patients in Korea. J Korean Med Sci 2020;35(7): e86.
[11] Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 63(3): 364-374. https://doi.org/10.1007/s11427-020-1643-8.
Yamamoto K, Hosogaya N, Sakamoto N, Yoshida H, Ishii H, Yatera K, et al. Efficacious inhibition of SARS-CoV-2 by targeting its main protease. Nat Commun 2021;11(1):4417. https://doi.org/10.1038/s41467-020-18233-x.

Tsiakos K, Tsakiris A, Tsibris G, Voutsinas PM, Panagopoulos P, Kosmidou M, et al. Early start of oral clarithromycin is associated with better outcome in COVID-19 of moderate severity: The ACHIEVE Open-Label Single-Arm Trial. Infect Dis Ther 2021;10(4):2333–51. https://doi.org/10.1007/s40121-021-00505-8.

Yamamoto K, Hosogaya N, Sakamoto N, Yoshida H, Iishi H, Yatera K, et al. Efficacy of clarithromycin in patients with mild COVID 19 pneumonia not receiving oxygen administration: Protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID 19 study). BMJ Open 2021;11(9):e053325.

Mukund V, Behera SK, Alam A, Nagaraju GP. Molecular docking analysis of nuclear factor-κB and genistein interaction in the context of breast cancer. Bioinformation 2019;15(1):11–7. https://doi.org/10.6026/97320630015011.

Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 2021;12(1):37. https://doi.org/10.1038/s41467-020-18237-7.

Tsakiris A, Tsibris G, Voutsinas PM, Panagopoulos P, Kosmidou M, et al. Early start of oral clarithromycin is associated with better outcome in COVID-19 of moderate severity: The ACHIEVE Open-Label Single-Arm Trial. Infect Dis Ther 2021;10(4):2333–51. https://doi.org/10.1007/s40121-021-00505-8.

Yamamoto K, Hosogaya N, Sakamoto N, Yoshida H, Iishi H, Yatera K, et al. Efficacy of clarithromycin in patients with mild COVID 19 pneumonia not receiving oxygen administration: Protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID 19 study). BMJ Open 2021;11(9):e053325.